dapsone has been researched along with Pemphigoid, Bullous in 78 studies
Pemphigoid, Bullous: A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This short note presents previous research data supporting a pilot study of metronomic dapsone during the entire course of glioblastoma treatment." | 8.02 | Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation. ( Kast, RE, 2021) |
| "Dapsone has been used successfully as adjuvant therapy for bullous pemphigoid (BP)." | 7.73 | Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. ( Bröcker, EB; Goebeler, M; Kraensel, R; Rzany, B; Schmidt, E; Sinkgraven, R; Zillikens, D, 2005) |
| "In an open study, a total of 18 patients with proven bullous pemphigoid (16 new patients and two in relapse) were treated with a trial of dapsone (17 patients) or sulphonimide (one patient)." | 7.67 | Dapsone as first line therapy for bullous pemphigoid. ( Millard, PR; Venning, VA; Wojnarowska, F, 1989) |
| "Current treatment of bullous pemphigoid (BP) is based on the long-term use of topical and/or systemic corticosteroids, which are associated with a high rate of adverse events and increased mortality." | 6.84 | An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. ( Aberer, E; Franke, A; Gläser, R; Hertl, M; Pfeiffer, C; Rzany, B; Schmidt, E; Schneider, S; Shimanovich, I; Sticherling, M; Werfel, T; Wilczek, A; Zillikens, D, 2017) |
| "Dapsone is a chemotherapeutic agent primarily used in treating leprosy, Pneumocystis jiroveci (previously carinii) pneumonia, and malaria." | 6.45 | Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. ( Ahmed, AR; Gürcan, HM, 2009) |
| " She started dapsone at the dosage of 1 mg/kg/day, maintaining low dose prednisone; this treatment was successfully followed by the dramatic disappearance of skin lesions and limb pain." | 5.46 | Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone. ( Cimaz, R; Corsello, G; Maggio, MC; Prinzi, E, 2017) |
| "Clobetasol propionate cream applied over the whole body is probably similarly effective as, and may cause less mortality than, oral prednisone for treating bullous pemphigoid." | 5.41 | Interventions for bullous pemphigoid. ( Anchan, VN; Boyle, RJ; Chi, CC; Kirtschig, G; Murrell, DF; Singh, S; Taghipour, K, 2023) |
| "We present the case of a 1-year-old boy diagnosed with mucous membrane pemphigoid by biopsy who was treated with rituximab (375 mg/m 2 intravenous infusion at 2-week interval administered twice) and stable with oral dapsone (2 mg·kg -1 ·d -1 )." | 4.12 | Surgical Management of Ocular Cicatricial Pemphigoid in a Pediatric Patient. ( Fideliz de la Paz, M; Martínez-Grau, A; Ollero, R; Soldevila, A, 2022) |
| "This short note presents previous research data supporting a pilot study of metronomic dapsone during the entire course of glioblastoma treatment." | 4.02 | Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation. ( Kast, RE, 2021) |
| "Dapsone has been used successfully as adjuvant therapy for bullous pemphigoid (BP)." | 3.73 | Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. ( Bröcker, EB; Goebeler, M; Kraensel, R; Rzany, B; Schmidt, E; Sinkgraven, R; Zillikens, D, 2005) |
| "We studied the precise correlation between ELISA values for BP180 NC16A and the alternations of disease activity in 5 patients with bullous pemphigoid (BP) during various treatments and tried to answer the question of how we can use ELISA to determine the timing of prednisolone (PSL) tapering." | 3.72 | Monitoring of ELISA for anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid. ( Esaki, C; Ichiki, Y; Izumi, T; Kitajima, Y, 2004) |
| " We examined a patient in whom bullous pemphigoid developed after she received enalapril for treatment of hypertension." | 3.68 | Antigen identification in drug-induced bullous pemphigoid. ( Meyer, LJ; Smith, EP; Taylor, TB; Zone, JJ, 1993) |
| "In an open study, a total of 18 patients with proven bullous pemphigoid (16 new patients and two in relapse) were treated with a trial of dapsone (17 patients) or sulphonimide (one patient)." | 3.67 | Dapsone as first line therapy for bullous pemphigoid. ( Millard, PR; Venning, VA; Wojnarowska, F, 1989) |
| "Current treatment of bullous pemphigoid (BP) is based on the long-term use of topical and/or systemic corticosteroids, which are associated with a high rate of adverse events and increased mortality." | 2.84 | An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. ( Aberer, E; Franke, A; Gläser, R; Hertl, M; Pfeiffer, C; Rzany, B; Schmidt, E; Schneider, S; Shimanovich, I; Sticherling, M; Werfel, T; Wilczek, A; Zillikens, D, 2017) |
| "Dapsone is a chemotherapeutic agent primarily used in treating leprosy, Pneumocystis jiroveci (previously carinii) pneumonia, and malaria." | 2.45 | Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. ( Ahmed, AR; Gürcan, HM, 2009) |
| "The target antigens in cicatricial pemphigoid appear to be lamina lucida proteins involved in human keratinocyte adhesion to extracellular matrix." | 2.40 | Cicatricial pemphigoid (benign mucous membrane pemphigoid). ( Bergfeld, WF; Terezhalmy, GT, 1998) |
| "A review of canine pemphigus vulgaris, pemphigus vegetans, pemphigus foliaceus, pemphigus erythematosus, and bullous pemphigoid shows them to share many clinicopathologic similarities with their human counterparts." | 2.36 | Pemphigus and pemphigoid in dog and man: comparative aspects. ( Lewis, RM; Scott, DW, 1981) |
| "Dapsone was also more likely to be discontinued because of AEs than mycophenolate (40% vs." | 1.91 | A 10-Year Review of the Management of Ocular Mucous Membrane Pemphigoid: A Private Practice Experience. ( Broadbent, T; Johnson, KB; Michels, KS; Rosenbaum, JT; Yarter, JT, 2023) |
| " She started dapsone at the dosage of 1 mg/kg/day, maintaining low dose prednisone; this treatment was successfully followed by the dramatic disappearance of skin lesions and limb pain." | 1.46 | Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone. ( Cimaz, R; Corsello, G; Maggio, MC; Prinzi, E, 2017) |
| "Anti-p200 pemphigoid is a recently described autoimmune subepidermal bullous dermatosis characterized by its target antigen and the associated anatomoclinical picture." | 1.39 | [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)]. ( Delaplace, M; Estève, E; Raffin, D; Roussel, A, 2013) |
| "Bullous pemphigoid is an autoimmune subepidermal blistering disease associated with autoantibodies against BP180 and BP230." | 1.36 | Immunoglobulin A antibodies against desmoglein 1, envoplakin, periplakin and BP230 in a patient with atypical bullous pemphigoid. ( Hashimoto, T; Ikeda, S; Mayuzumi, N; Yamaki, F, 2010) |
| "Dapsone was efficient in 26% of patients." | 1.32 | [Pemphigoid gestationis: a study of 15 cases]. ( Bouassida, S; Boudaya, S; Marrekchi, S; Meziou, TJ; Turki, H; Zahaf, A, 2003) |
| "Anti-p200 pemphigoid is a recently defined subepidermal immunobullous disease." | 1.31 | Anti-p200 pemphigoid: diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease. ( Egan, CA; Yancey, KB; Yee, C; Zillikens, D, 2002) |
| "Oral pemphigoid is a distinct clinical subset of CP." | 1.30 | Oral pemphigoid. Subset of cicatricial pemphigoid? ( Ahmed, AR; Mobini, N; Nagarwalla, N, 1998) |
| "Dapsone was stopped on day 15 due to poor hematological tolerance." | 1.30 | [Sporadic superficial pemphigus in the child: 2 cases]. ( Bourrat, E; Ducloy, G; Flageul, B; Moraillon, I; Morel, P; Reymond, JL; Rybojad, M; Vignon-Pennamen, MD, 1999) |
| "Dapsone was added directly to the neutrophils or to the antibody source in concentrations of 0-50 micrograms/ml (pharmacologic range)." | 1.29 | Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. ( Gammon, WR; Hendrix, JD; Kadunce, DP; Thuong-Nguyen, V; Zone, JJ, 1993) |
| "Bullous pemphigoid is a clinically heterogeneous disease although little is known of the factors affecting its course and outcome." | 1.28 | Lack of predictive factors for the clinical course of bullous pemphigoid. ( Venning, VA; Wojnarowska, F, 1992) |
| "Dermatitis herpetiformis, pemphigus vulgaris, and bullous pemphigoid are uncommon, but not rare, blistering diseases." | 1.28 | Three blistering diseases. Why proper management is critical. ( Wooldridge, WE, 1990) |
| "Bullous pemphigoid is a chronic blistering disorder characterized by specific clinical, histologic, and immunofluorescent findings." | 1.27 | Bullous pemphigoid and prurigo nodularis. ( Dahl, MV; Roenigk, RK, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (17.95) | 18.7374 |
| 1990's | 9 (11.54) | 18.2507 |
| 2000's | 14 (17.95) | 29.6817 |
| 2010's | 31 (39.74) | 24.3611 |
| 2020's | 10 (12.82) | 2.80 |
| Authors | Studies |
|---|---|
| Ollero, R | 1 |
| Soldevila, A | 1 |
| Fideliz de la Paz, M | 1 |
| Martínez-Grau, A | 1 |
| Viglizzo, G | 1 |
| Herzum, A | 1 |
| Cozzani, E | 1 |
| Occella, C | 1 |
| Parodi, A | 1 |
| Johnson, KB | 1 |
| Rosenbaum, JT | 1 |
| Yarter, JT | 1 |
| Broadbent, T | 1 |
| Michels, KS | 1 |
| Singh, S | 1 |
| Kirtschig, G | 1 |
| Anchan, VN | 1 |
| Chi, CC | 1 |
| Taghipour, K | 1 |
| Boyle, RJ | 1 |
| Murrell, DF | 1 |
| Davies, OMT | 1 |
| Hill, IM | 1 |
| Chiu, YE | 1 |
| Morris, LM | 1 |
| Lewis, HA | 1 |
| Cornelius, LA | 1 |
| Chen, DY | 1 |
| Rosman, IS | 1 |
| Mangin, MA | 1 |
| Kanitakis, J | 1 |
| Jullien, D | 1 |
| Lesort, C | 1 |
| Kast, RE | 1 |
| Siller, A | 1 |
| Shalabi, MMK | 1 |
| Jebain, J | 1 |
| Tyring, SK | 1 |
| Rodriguez Baisi, K | 1 |
| Wentworth, A | 1 |
| Chattha, AJ | 1 |
| DiCaudo, DJ | 1 |
| Mangold, A | 1 |
| Nelson, SA | 1 |
| Siegfried, E | 1 |
| Wieland, CN | 1 |
| Tollefson, M | 1 |
| Murthy, S | 1 |
| Schilf, P | 1 |
| Patzelt, S | 1 |
| Thieme, M | 1 |
| Becker, M | 1 |
| Kröger, L | 1 |
| Bremer, T | 1 |
| Derenda-Hell, A | 1 |
| Knebel, L | 1 |
| Fagiani, F | 1 |
| Ibrahim, SM | 1 |
| Schmidt, E | 9 |
| Zillikens, D | 9 |
| Sadik, CD | 1 |
| Maggio, MC | 1 |
| Corsello, G | 1 |
| Prinzi, E | 1 |
| Cimaz, R | 1 |
| Patsatsi, A | 2 |
| Meltzanidou, P | 1 |
| Katafigiotis, S | 1 |
| Sotiriadis, D | 1 |
| Lambropoulos, A | 1 |
| Sticherling, M | 1 |
| Franke, A | 1 |
| Aberer, E | 1 |
| Gläser, R | 1 |
| Hertl, M | 1 |
| Pfeiffer, C | 1 |
| Rzany, B | 2 |
| Schneider, S | 1 |
| Shimanovich, I | 2 |
| Werfel, T | 1 |
| Wilczek, A | 1 |
| Schmidgen, MI | 1 |
| Butsch, F | 1 |
| Schadmand-Fischer, S | 1 |
| Steinbrink, K | 1 |
| Grabbe, S | 1 |
| Weidenthaler-Barth, B | 1 |
| Loquai, C | 1 |
| Iwata, H | 1 |
| Żychowska, M | 1 |
| Hübner, F | 1 |
| Kasperkiewicz, M | 2 |
| Knuth-Rehr, D | 1 |
| Hübner, J | 1 |
| Süfke, S | 1 |
| Muck, P | 1 |
| Hattori, M | 1 |
| Shimizu, A | 1 |
| Ishikawa, O | 2 |
| Cortés-Pinto, C | 1 |
| Baradad Brusau, M | 1 |
| Vilardell Vilellas, F | 1 |
| Mascaró Galy, JM | 1 |
| Arco Huguet, N | 1 |
| Soria Gili, X | 1 |
| Kyriakou, A | 1 |
| Werth, VP | 1 |
| Varpuluoma, O | 1 |
| Jokelainen, J | 1 |
| Försti, AK | 1 |
| Timonen, M | 1 |
| Huilaja, L | 1 |
| Tasanen, K | 1 |
| Mori, T | 1 |
| Yamamoto, T | 1 |
| Schulze, F | 2 |
| van Beek, N | 2 |
| Terheyden, P | 1 |
| Raffin, D | 1 |
| Delaplace, M | 1 |
| Roussel, A | 1 |
| Estève, E | 1 |
| Dolenc-Voljč, M | 1 |
| Žgavec, B | 1 |
| Vizjak, A | 1 |
| Tenyi, V | 1 |
| Luzar, B | 1 |
| Meier, M | 1 |
| Nitschke, M | 1 |
| Marovt, M | 1 |
| El Shabrawi-Caelen, L | 1 |
| Seminario-Vidal, L | 1 |
| Sami, N | 1 |
| Miller, J | 1 |
| Theos, A | 1 |
| Carrozzo, M | 1 |
| Chen, TJ | 1 |
| Lai, PC | 1 |
| Yang, LC | 1 |
| Kuo, TT | 1 |
| Hong, HS | 1 |
| Gajic-Veljic, M | 1 |
| Nikolic, M | 1 |
| Medenica, L | 1 |
| Gürcan, HM | 1 |
| Ahmed, AR | 3 |
| Veien, NK | 1 |
| Lupi, F | 1 |
| Masini, C | 1 |
| Ruffelli, M | 1 |
| Puddu, P | 1 |
| Cianchini, G | 1 |
| Yamaki, F | 1 |
| Mayuzumi, N | 1 |
| Ikeda, S | 1 |
| Hashimoto, T | 3 |
| Bernard, P | 1 |
| Charneux, J | 1 |
| Rosmaninho, A | 1 |
| Sanches, M | 1 |
| Oliveira, A | 1 |
| Alves, R | 1 |
| Selores, M | 1 |
| Scheerder, IW | 1 |
| Stoelhorst, GM | 1 |
| Magro, CM | 1 |
| Wu, R | 1 |
| Kikuchi, K | 1 |
| Natsuga, K | 1 |
| Shinkuma, S | 1 |
| Nishie, W | 2 |
| Kajita, S | 1 |
| Sato, H | 1 |
| Shimizu, H | 3 |
| Guilabert, A | 1 |
| Lozano, F | 1 |
| Iranzo, P | 1 |
| Suárez-Casasús, B | 1 |
| Martinez-De Pablo, I | 1 |
| Julià, M | 1 |
| Mascaró, JM | 1 |
| Munsch, C | 1 |
| Prey, S | 1 |
| Joly, P | 1 |
| Meyer, N | 1 |
| Lamant, L | 1 |
| Livideanu, C | 1 |
| Viraben, R | 1 |
| Paul, C | 1 |
| Nobbe, S | 1 |
| Weibel, L | 1 |
| Kuehne, A | 1 |
| Gobbi, S | 1 |
| Kerl, K | 1 |
| Cozzio, A | 1 |
| Boudaya, S | 1 |
| Turki, H | 1 |
| Meziou, TJ | 1 |
| Marrekchi, S | 1 |
| Bouassida, S | 1 |
| Zahaf, A | 1 |
| Ben Jazia, H | 1 |
| Fenniche, S | 1 |
| Marrak, H | 1 |
| Ben Jennet, S | 1 |
| Zghal, M | 1 |
| Ben Ammar, F | 1 |
| Mokhtar, I | 1 |
| Izumi, T | 1 |
| Ichiki, Y | 1 |
| Esaki, C | 1 |
| Kitajima, Y | 1 |
| Kraensel, R | 1 |
| Goebeler, M | 1 |
| Sinkgraven, R | 1 |
| Bröcker, EB | 3 |
| Motegi, S | 1 |
| Abe, M | 2 |
| Tamura, A | 1 |
| Ishii, N | 2 |
| Hofmann, SC | 1 |
| Bruckner-Tuderman, L | 1 |
| Yamane, N | 1 |
| Sawamura, D | 1 |
| Kodama, K | 1 |
| Adachi, K | 1 |
| Nakamura, H | 1 |
| Arash, A | 1 |
| Shirin, L | 1 |
| Piamphongsant, T | 2 |
| Barranco, VP | 1 |
| Scott, DW | 1 |
| Lewis, RM | 1 |
| Bauer, R | 1 |
| Orfanos, CE | 1 |
| Jablonska, S | 1 |
| Chorzelski, T | 1 |
| Danno, K | 1 |
| Okamoto, H | 1 |
| Miyauchi, H | 1 |
| Imamura, S | 1 |
| Darling, TN | 1 |
| Cardenas, AA | 1 |
| Beard, JS | 1 |
| Sau, P | 1 |
| Yee, CL | 1 |
| Zone, JJ | 3 |
| Yancey, KB | 2 |
| Smith, EP | 1 |
| Taylor, TB | 1 |
| Meyer, LJ | 1 |
| Thuong-Nguyen, V | 1 |
| Kadunce, DP | 1 |
| Hendrix, JD | 1 |
| Gammon, WR | 1 |
| Bouscarat, F | 1 |
| Chosidow, O | 1 |
| Picard-Dahan, C | 1 |
| Sakiz, V | 1 |
| Crickx, B | 1 |
| Prost, C | 1 |
| Roujeau, JC | 1 |
| Revuz, J | 1 |
| Belaich, S | 1 |
| Mobini, N | 1 |
| Nagarwalla, N | 1 |
| Terezhalmy, GT | 1 |
| Bergfeld, WF | 1 |
| Rybojad, M | 1 |
| Ducloy, G | 1 |
| Reymond, JL | 1 |
| Moraillon, I | 1 |
| Flageul, B | 1 |
| Vignon-Pennamen, MD | 1 |
| Morel, P | 1 |
| Bourrat, E | 1 |
| Obe, K | 1 |
| Reimer, S | 1 |
| Kruse, N | 1 |
| Egan, CA | 1 |
| Yee, C | 1 |
| Venning, VA | 2 |
| Wojnarowska, F | 2 |
| Wooldridge, WE | 1 |
| Hisler, BM | 1 |
| Blumenthal, NC | 1 |
| Aronson, PJ | 1 |
| Hashimoto, K | 1 |
| Rudner, EJ | 1 |
| Hayakawa, K | 1 |
| Amagai, M | 1 |
| Harada, T | 1 |
| Nishikawa, T | 1 |
| Yamasaki, Y | 1 |
| Jeffes, EW | 1 |
| Millard, PR | 1 |
| Camisa, C | 1 |
| Neff, JC | 1 |
| Rossana, C | 1 |
| Barrett, JL | 1 |
| Roenigk, RK | 1 |
| Dahl, MV | 1 |
| Rogers, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid: A Randomized Controlled Trial[NCT05984381] | Phase 4 | 62 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| Rituximab in the Treatment of Patients With Bullous Pemphigoid[NCT00286325] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Peripheral blood B cell number at week 24 compared to B cell number at week 0 (NCT00286325)
Timeframe: Week 0 and at 24 weeks
| Intervention | B cells per microliter (Median) |
|---|---|
| Treated | 3.99 |
IgG antibodies against BP 180 measured in units (by ELISA) for each participant at week 0 compared to value at week 24, (NCT00286325)
Timeframe: Week 0 and at 24 weeks
| Intervention | Elisa Units (Median) |
|---|---|
| Treated | 40.5 |
The first study visit in which patient reported and was confirmed to have no new blister or lesion formation . (NCT00286325)
Timeframe: 1 year
| Intervention | Days (Median) |
|---|---|
| Treated | 57 |
Subject systemic corticosteroid dosage at week 24 was 25% of starting dose or 10 mg/day of prednisone or less (NCT00286325)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Treated | 7 |
The primary safety endpoint is the occurrence of treatment emergent adverse events including infections, infusion reactions and disease progression. These were determined by clinical evaluation and laboratory questions. Disease progression is defined as development of new blisters despite therapy. These are reported as the number of participants with a study related SAE. (NCT00286325)
Timeframe: 1 year
| Intervention | participants (Number) | ||
|---|---|---|---|
| Treatment emergent adverse events | Infusion reactions | Disease Progression | |
| Treated | 0 | 0 | 1 |
9 reviews available for dapsone and Pemphigoid, Bullous
| Article | Year |
|---|---|
Interventions for bullous pemphigoid.
Topics: Azathioprine; Clobetasol; Dapsone; Doxycycline; Humans; Methylprednisolone; Niacinamide; Pemphigoid, | 2023 |
A 13-year-old girl with recurrent oral ulcers.
Topics: Adolescent; Autoimmune Diseases; Dapsone; Diagnosis, Differential; Female; Humans; Mouth Mucosa; Ora | 2019 |
Bullous pemphigoid in adolescence.
Topics: Adolescent; Anti-Infective Agents; Azathioprine; Child; Dapsone; Female; Glucocorticoids; Humans; Im | 2019 |
Concomitant bullous pemphigoid and dermatitis herpetiformis.
Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Autoantibodies; Autoantigens; Basement Membra | 2013 |
Bullous pemphigoid in a renal transplant recipient: a case report and review of the literature.
Topics: Administration, Cutaneous; Anti-Infective Agents; Clobetasol; Dapsone; Doxycycline; Fatal Outcome; G | 2009 |
Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.
Topics: Dapsone; Humans; Pemphigoid, Bullous; Pemphigus | 2009 |
[Bullous pemphigoid: a review].
Topics: Aged; Azathioprine; Clobetasol; Combined Modality Therapy; Dapsone; Dose-Response Relationship, Drug | 2011 |
Pemphigus and pemphigoid in dog and man: comparative aspects.
Topics: Animals; Aurothioglucose; Dapsone; Dog Diseases; Dogs; Fluorescent Antibody Technique; Humans; Mouth | 1981 |
Cicatricial pemphigoid (benign mucous membrane pemphigoid).
Topics: Adult; Anti-Infective Agents; Dapsone; Diagnosis, Differential; Epidermolysis Bullosa Acquisita; Fem | 1998 |
4 trials available for dapsone and Pemphigoid, Bullous
| Article | Year |
|---|---|
An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Azathioprine; Dapsone; Dermatologic Agents; Dru | 2017 |
Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma.
Topics: Antibodies, Monoclonal, Humanized; Complement C3; Dapsone; Dose-Response Relationship, Drug; Double- | 2017 |
Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Aut | 2000 |
Dapsone and sulfapyridine therapy of pemphigoid diseases.
Topics: Adult; Aged; Clinical Trials as Topic; Dapsone; Female; Humans; Male; Middle Aged; Pemphigoid, Benig | 1986 |
65 other studies available for dapsone and Pemphigoid, Bullous
| Article | Year |
|---|---|
Surgical Management of Ocular Cicatricial Pemphigoid in a Pediatric Patient.
Topics: Child; Dapsone; Entropion; Humans; Infant; Male; Pemphigoid, Benign Mucous Membrane; Pemphigoid, Bul | 2022 |
Intravenous immunoglobulins in infantile dyshidrosiform bullous pemphigoid refractory to steroids and dapsone.
Topics: Dapsone; Humans; Immunoglobulins, Intravenous; Pemphigoid, Bullous; Steroids | 2022 |
A 10-Year Review of the Management of Ocular Mucous Membrane Pemphigoid: A Private Practice Experience.
Topics: Dapsone; Female; Humans; Immunosuppressive Agents; Male; Mucous Membrane; Pemphigoid, Benign Mucous | 2023 |
Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
Topics: Aged; Antimalarials; Dapsone; Drug Eruptions; Drug Therapy, Combination; Glucocorticoids; Humans; Im | 2020 |
Dermpath & Clinic: Lichen planus pemphigoides.
Topics: Biopsy; Dapsone; Dermatologic Agents; Diagnosis, Differential; Glucocorticoids; Humans; Immunosuppre | 2020 |
Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.
Topics: Cimetidine; Dapsone; Glioblastoma; Humans; Interleukin-8; Pemphigoid, Bullous; Pharmaceutical Prepar | 2021 |
A Recurrent, Painful, and Vesicular Rash in a Dermatomal Distribution.
Topics: Biopsy; Dapsone; Dermatologic Agents; Diagnosis, Differential; Female; Fluorescent Antibody Techniqu | 2021 |
A rare case of childhood mucous membrane pemphigoid involving the oral and genital mucosa.
Topics: Aged; Child; Dapsone; Female; Genitalia; Humans; Mouth Mucosa; Mucous Membrane; Pemphigoid, Benign M | 2021 |
Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases.
Topics: Animals; Cell Adhesion Molecules; Dapsone; Disease Models, Animal; Dose-Response Relationship, Drug; | 2021 |
Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone.
Topics: Antimalarials; Child; Dapsone; Female; Humans; Lupus Erythematosus, Systemic; Pemphigoid, Bullous | 2017 |
Chronic bullous disease of childhood with IgG reactivity to p200 antigen.
Topics: Autoantibodies; Biopsy, Needle; Child, Preschool; Dapsone; Follow-Up Studies; Humans; Immunoglobulin | 2017 |
Dapsone is a potentially useful adjuvant therapy for bullous pemphigoid.
Topics: Combined Modality Therapy; Dapsone; Humans; Pemphigoid, Bullous | 2017 |
Dapsone: a forgotten and underestimated treatment option for bullous pemphigoid?
Topics: Dapsone; Humans; Pemphigoid, Bullous | 2017 |
Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption.
Topics: Aged; Aged, 80 and over; Antimalarials; Autoantibodies; Clobetasol; Dapsone; Female; Glucocorticoids | 2018 |
Development of pemphigoid nodularis after remission of bullous lesions.
Topics: Aged; Anti-Infective Agents; Dapsone; Female; Glucocorticoids; Humans; Methylprednisolone; Pemphigoi | 2019 |
Bullous pemphigoid in a 3-month-old infant after vaccination.
Topics: Anti-Infective Agents; Autoantibodies; Blister; Dapsone; Humans; Infant; Male; Pemphigoid, Bullous; | 2019 |
Dermatitis Herpetiformis and Celiac Disease Increase the Risk of Bullous Pemphigoid.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Celiac Disease; Dapsone; Dermatitis Herpetifor | 2019 |
Bullous pemphigoid developed on nummular eczema lesions.
Topics: Administration, Cutaneous; Administration, Oral; Betamethasone; Biopsy; Dapsone; Drug Therapy, Combi | 2019 |
[Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
Topics: Aged; Autoantibodies; Autoantigens; Clobetasol; Dapsone; Drug Resistance; Humans; Immunoglobulin G; | 2013 |
Figurate erythema in a patient with bullous pemphigoid and Toxocara infection.
Topics: Aged; Animals; Anti-Bacterial Agents; Biopsy, Needle; Dapsone; Erythema; Female; Fluorescent Antibod | 2013 |
Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents; Autoantibodies; Dapsone; F | 2014 |
Purpuric bullous pemphigoid.
Topics: Aged, 80 and over; Biopsy; Dapsone; Diagnosis, Differential; Drug Administration Schedule; Drug Ther | 2015 |
Mycophenolate mofetil therapy for pediatric bullous pemphigoid.
Topics: Anti-Bacterial Agents; Clindamycin; Dapsone; Diagnosis, Differential; Drug Resistance; Humans; Immun | 2015 |
A reappraisal of diagnostic criteria for mucous membrane pemphigoid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dapsone; Diagnosis, Differential; Glucocorticoids; Humans; | 2009 |
Juvenile bullous pemphigoid: the presentation and follow-up of six cases.
Topics: Adolescent; Child; Child, Preschool; Dapsone; Female; Fluocinolone Acetonide; Follow-Up Studies; Hum | 2010 |
Bullous pemphigoid masquerading as recurrent vesicular hand eczema.
Topics: Adrenal Cortex Hormones; Autoantibodies; Autoantigens; Basement Membrane; Collagen Type XVII; Comple | 2010 |
Dyshidrosiform palmoplantar pemphigoid in a young man: response to dapsone.
Topics: Adrenal Cortex Hormones; Autoantibodies; Autoantigens; Basement Membrane; Biopsy; Collagen Type XVII | 2010 |
Immunoglobulin A antibodies against desmoglein 1, envoplakin, periplakin and BP230 in a patient with atypical bullous pemphigoid.
Topics: Aged, 80 and over; Autoantibodies; Basement Membrane; Dapsone; Desmoglein 1; Female; Humans; Immunog | 2010 |
Lichen planus pemphigoides induced by a weight reduction drug.
Topics: Adult; Anti-Infective Agents; Anti-Obesity Agents; Dapsone; Female; Humans; Lichen Planus; Pemphigoi | 2011 |
[A boy with pruritus and blisters].
Topics: Anti-Infective Agents; Child, Preschool; Dapsone; Humans; Immunoglobulin A; Male; Pemphigoid, Bullou | 2011 |
Anti-laminin 5 pemphigoid: a case report of a benign cutaneous confined non-cicatricial variant.
Topics: Aged; Autoantibodies; Cell Adhesion Molecules; Dapsone; Humans; Kalinin; Male; Pemphigoid, Bullous | 2012 |
Subepidermal blistering disease with 3 distinct autoantibodies: anti-BP230, anti-laminin gamma-1, and anti-laminin-332.
Topics: Adult; Autoantibodies; Basement Membrane; Carrier Proteins; Cell Adhesion Molecules; Cytoskeletal Pr | 2011 |
A case of aggressive bullous pemphigoid associated with the defective functional variant of Fc gamma receptor IIb: implications for pathogenesis?
Topics: Aged; Alleles; Autoantibodies; Autoantigens; Azathioprine; Collagen Type XVII; Cyclophosphamide; Dap | 2011 |
[Anti-p200 pemphigoid: a spectacular response to dapsone].
Topics: Aged, 80 and over; Antibody Specificity; Autoantibodies; Autoantigens; Clobetasol; Complement C3; Da | 2011 |
PLEVA pemphigoides - synchronous features of PLEVA and bullous pemphigoid.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Child; Dapsone; Humans; Male; Pemphigoid, Bullous; P | 2013 |
[Pemphigoid gestationis: a study of 15 cases].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dapsone; Drug Therapy, Comb | 2003 |
[Bullous pemphigoid in children. Report of three cases].
Topics: Age Distribution; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Dapsone; Female; | 2002 |
Monitoring of ELISA for anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Autoantibodies; Autoantigens; Collagen Type XVII; Da | 2004 |
Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents; Clobetasol; Dapsone; | 2005 |
Childhood bullous pemphigoid successfully treated with diaminodiphenyl sulfone.
Topics: Adolescent; Autoantibodies; Dapsone; Female; Humans; Pemphigoid, Bullous; Skin | 2005 |
[Bullous pemphigoid: diagnostics and new therapeutic strategies].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Autoantibodies; Azathioprine; Biopsy | 2006 |
Anti-p200 pemphigoid in a 17-year-old girl successfully treated with systemic corticosteroid and dapsone.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Dapsone; Female; Glucocorticoid | 2007 |
The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dapsone; Drug Combinations; Female; Glucocorti | 2008 |
Dapsone for the treatment of vesiculo-bullous and pustular diseases.
Topics: Dapsone; Dermatitis Herpetiformis; Humans; Keratoderma, Palmoplantar; Pemphigoid, Bullous; Skin Dise | 1982 |
Dapsone--other indications.
Topics: Acne Vulgaris; Adolescent; Animals; Dapsone; Dermatitis Herpetiformis; Humans; Male; Pemphigoid, Bul | 1982 |
Dapsone for the treatment of bullous pemphigoid.
Topics: Adolescent; Adult; Aged; Autoantibodies; Autoimmune Diseases; Child; Dapsone; Female; Humans; Male; | 1983 |
[Pemphigus herpetiformis: a clinical variant of pemphigus vulgaris].
Topics: Aged; Autoantibodies; Complement C3; Dapsone; Dermatitis Herpetiformis; Diagnosis, Differential; Epi | 1980 |
When and how to use sulfones in bullous diseases.
Topics: Adrenal Cortex Hormones; Child; Chronic Disease; Dapsone; Dermatitis Herpetiformis; Diagnosis, Diffe | 1981 |
Bullous pemphigoid and antinuclear antibodies. Unmasking of basement membrane fluorescence in sodium chloride-treated substrates.
Topics: Animals; Antibodies, Antinuclear; Basement Membrane; Binding Sites, Antibody; Complement C3; Dapsone | 1982 |
A child with antibodies targeting both linear IgA bullous dermatosis and bullous pemphigoid antigens.
Topics: Autoantibodies; Autoantigens; Basement Membrane; Child, Preschool; Complement C3; Dapsone; Epidermis | 1995 |
Antigen identification in drug-induced bullous pemphigoid.
Topics: Aged; Antigens; Dapsone; Enalapril; Female; Humans; Hypertension; Pemphigoid, Bullous | 1993 |
Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses.
Topics: Adult; Basement Membrane; Binding Sites, Antibody; Cell Adhesion; Cell Survival; Dapsone; Dose-Respo | 1993 |
Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Betamethasone Val | 1996 |
Oral pemphigoid. Subset of cicatricial pemphigoid?
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Basement Membrane; Dapsone; Female; Follow-Up Studies; G | 1998 |
[Sporadic superficial pemphigus in the child: 2 cases].
Topics: Adult; Child; Child, Preschool; Dapsone; Drug Therapy, Combination; Facial Dermatoses; Female; Fluor | 1999 |
The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Autoantigens; Cells, Cultured; Che | 2001 |
Anti-p200 pemphigoid: diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease.
Topics: Autoantibodies; Autoimmune Diseases; Biopsy, Needle; Dapsone; Drug Therapy, Combination; Follow-Up S | 2002 |
Lack of predictive factors for the clinical course of bullous pemphigoid.
Topics: Aged; Aged, 80 and over; Autoimmune Diseases; Azathioprine; Dapsone; Drug Therapy, Combination; Fema | 1992 |
Three blistering diseases. Why proper management is critical.
Topics: Adrenal Cortex Hormones; Adult; Dapsone; Dermatitis Herpetiformis; Diet; Female; Glutens; Humans; Ma | 1990 |
Bullous pemphigoid in psoriatic lesions.
Topics: Dapsone; Humans; Male; Middle Aged; Pemphigoid, Bullous; Psoriasis; Skin Diseases, Vesiculobullous | 1989 |
Vesicular pemphigoid--ultrastructural and immunoelectron microscopic study.
Topics: Aged; Basement Membrane; Complement C3; Dapsone; Drug Therapy, Combination; Female; Humans; Immunogl | 1989 |
Adjuvant therapy of bullous pemphigoid with dapsone.
Topics: Adult; Aged; Azathioprine; Dapsone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pe | 1989 |
Dapsone as first line therapy for bullous pemphigoid.
Topics: Aged; Aged, 80 and over; Dapsone; Female; Humans; Male; Middle Aged; Pemphigoid, Bullous; Recurrence | 1989 |
Bullous lichen planus: diagnosis by indirect immunofluorescence and treatment with dapsone.
Topics: Adult; Dapsone; Diagnosis, Differential; Female; Fluorescent Antibody Technique; Humans; Lichen Plan | 1986 |
Bullous pemphigoid and prurigo nodularis.
Topics: Aged; Dapsone; Female; Fluorescent Antibody Technique; Humans; Immunoglobulins; Pemphigoid, Bullous; | 1986 |